On Monday, the United States Supreme Court set aside the Court of Appeals decision in Association for Molecular Pathology v Myriad Genetics (Myriad Genetics case), ordering the Court of Appeals to reconsider its finding that gene patents for the detection of inheritable breast cancer were valid in light of the Supreme Court’s subsequent decision in Mayo Collaborative Services v Prometheus Laboratories Inc (Prometheus Laboratories case) handed down last week.

The United States Supreme Court found last week that the claims of Prometheus’ diagnostic method patents were invalid.